Adalimumab in Active and Inactive, Non-Infectious Uveitis: Global Results from the VISUAL I and VISUAL II Trials

201832 citationsJournal Articlehybrid Open Access

Authors

Hiroshi Gotô · Tokyo Medical University

Masahiro Zako

Kenichi Namba · Hokkaido University

Noriyasu Hashida · Osaka University

Toshikatsu Kaburaki · The University of Tokyo

Masanori Miyazaki · Kyushu University

Koh‐Hei Sonoda · Kyushu University

Abstract

Adalimumab lowered time to TF versus placebo in the integrated population; no consistent trends were observed in Japan substudies. Safety results were consistent between studies.

Topics & Keywords

Ocular Diseases and Behçet’s Syndrome Retinal and Optic Conditions Systemic Lupus Erythematosus Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Ocular Immunology and Inflammation

Volume 27, Issue 1, pp. 40-50

DOI: 10.1080/09273948.2018.1491605

Field-Weighted Citation Impact: 3.04